New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ALKS;LTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:14 EDTALKSAlkermes proprietary programs remain on track, says Leerink
Subscribe for More Information
08:09 EDTALKSAlkermes pipeline value set to come into focus, says FBR Capital
FBR Capital says investor sentiment toward Alkermes will "meaningfully shift" over the next 18 months as results from key trials become available. With an FDA action date of August 22, 2015, FBR believes the commercial potential of aripiprazole lauroxil may not be known until 2016. It thinks the 2016 results from the Phase III program of ALKS 5461, a potential treatment for major depressive disorder, may be more important. It sees the company's pipeline value coming into focus over the next six to 18 months and keeps a Market Perform rating on Alkermes following the company's Q3 results.
October 29, 2014
07:13 EDTALKSAlkermes reports Q3 AMPYRA, FAMPYRA revenues $16.5M
Subscribe for More Information
07:11 EDTALKSAlkermes says entering Q4 with 'strong momentum'
Subscribe for More Information
07:09 EDTALKSAlkermes sees FY14 free cash flow $20M
Subscribe for More Information
07:05 EDTALKSAlkermes sees FY14 EPS 19c-32c consensus 27c
Subscribe for More Information
07:04 EDTALKSAlkermes reports Q3 EPS 3c, consensus 2c
Subscribe for More Information
October 24, 2014
08:41 EDTLTMLife Time Fitness will convert to REIT, says Stifel
Following Life Time Fitness' Q3 results conference call, Stifel says the question is not if but when the company will convert to a REIT. The firm notes that the company's revenue comp guidance has improved, and it thinks the business is well-positioned to deliver enhanced returns going forward. The firm keeps a Buy rating on the shares.
October 23, 2014
10:42 EDTLTMHigh option volume stocks
High option volume stocks: ALIM ROC CAKE MDXG SMH CFX CRI INFN LTM
08:08 EDTLTMLife Time Fitness narrows FY14 EPS view to $3.03-$3.08 from $3.00-$3.10
Subscribe for More Information
08:07 EDTLTMLife Time Fitness reports Q3 adjusted EPS 88c, consensus 86c
Subscribe for More Information
06:51 EDTALKSAlkermes concerns removed with FDA acceptance, says Citigroup
Subscribe for More Information
October 22, 2014
11:14 EDTLTMHigh option volume stocks
Subscribe for More Information
07:02 EDTALKSAlkermes aripiprazole lauroxil NDA accepted for filing by FDA
Subscribe for More Information
October 21, 2014
07:54 EDTALKSLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use